Telo Genomics Corp. · TSXV:TELO
Telo Genomics — Investor Presentation (December 2025)
19 slides from Telo Genomics's investor presentation, December 2025
Slide 1: Transforming Cancer Diagnostic with AI and Liquid Biopsy
Corporate Update Transforming Cancer Diagnostic with AI and Liquid Biopsy TSXV: TELO ∣ OTCQB: TDSGF https://www.telodx.com 2025 TELOGENOMICS . TSXV: TELO 2024 TELOGENOMICS . TSXV:
Slide 2: Forward Looking Statement & Disclosures
Forward Looking Statement & Disclosures This document and any attachments are intended for information purposes only and should not be construed as on offer or solicitation for the sale of securities. Statements in this presentation include forward-looking statements within the meaning of certain se
Slide 3: MRD - The Key to Staying a Step Ahead of Cancer
MRD - The Key to Staying a Step Ahead of Cancer Too late, too often: Telo Genomics Minimal Residual Disease (MRD) test makes cancer detection faster and sharper. • Late detection of relapse Telo Genomics’ proprietary • Overtreatment and undertreatment 3D telomere platform directly addresses key limi
Slide 4: Why Invest in Telo Genomics?
Why Invest in Telo Genomics? Clinically Validated & De-Risked Backed by studies in over 3,000 patients, 190+ publications – across oncology and CNS (Alzheimer’s) Breakthrough AI + Telomere Technology First and only platform using telomere architecture + AI to detect aggressive cancer cells, in addit
Slide 5: Telo Genomics Will Disrupt the MRD Business
Telo Genomics Will Disrupt the MRD Business Telo Genomics MRD: Delivering Superior Sensitivity in Blood-Based Cancer Monitoring and Aggressive Cell Detection >$30M Canadian Grant Funding + $20M investment funding Clinically Proven – Validated by top-tier U.S. cancer centers Liquid Biopsy Platform –
Slide 6: Cracking Cancer's Code with the Telo Platform
Cracking Cancer’s Code with the Telo Platform Telomere parameters quantified by TELOVIEW® Healthy cell Diseased cell the 3D spatial structure of each telomere is visualized and digitally analyzed. The diseased cell show aggregates, extremely small telomeres, nuclear spaces without telomeres and diff
Slide 7: Strongly Derisked Platform
Strongly Derisked Platform >$30M Canadian Grant Funding Telo’s proprietary Telomere platform supports multiple vertical applications—from oncology diagnostics and MRD monitoring to therapy management and longevity—across cancer and non-cancer indications. Platform Technology has been developed – fut
Slide 8: Clinical Partners Extensively Evaluated the Platform
Clinical Partners Extensively Evaluated the Platform 2025 TELOGENOMICS . TSXV: TELO 8 Confidential
Slide 9: Liquid Biopsy: A Game-Changer
Liquid Biopsy: A Game-Changer Better than Standard biopsy - Safer, faster, cheaper ❑ Minimally invasive ❑ Truly representative of the disease (measures not just the biopsied tissue area) ❑ Real-time monitoring ❑ Lower cost and convenience 2025 TELOGENOMICS . TSXV: TELO 9 Confidential
Slide 10: AI is Revolutionizing Cancer Detection
AI is Revolutionizing Cancer Detection Eliminates pathologist subjectivity, “Automates tedious manual steps” Automated cell identification: AI can recognize and classify different cell types with high accuracy. Quantitative analysis: AI can measure features like size, shape, and staining intensity P
Slide 11: Capturing the $4.5 B MRD Market opportunity
Capturing the $4.5 B MRD Market opportunity FDA recognition in April 2024 has allowed MRD to be used in clinical trials as a surrogate endpoint, speeding up drug development. Market Size a & Forecast * Key investment drivers include: • 2024 Market size: US$ 2.5 Billion • Rising cancer incidence, par
Slide 12: Minimum Residual Disease (MRD) for Multiple Myeloma
Minimum Residual Disease (MRD) for Multiple Myeloma Key criteria for extension of the relapse: MRD sensitivity, Ability for easy monitoring, Ability to identify aggressive cells Clinical disease progression Sensitivity of current technologies: Telo Genomics’ technology is 10-100-fold more sensitive
Slide 13: Key Advantages of Telo's MRD Technology
Key Advantages of Telo’s MRD Technology • Versatile across multiple sample types — including liquid biopsy, tissue, and bone marrow. • Enhanced sensitivity — detects disease down to 10⁻⁷, exceeding the industry standard of 10⁻⁶ (Adaptive). • Lower retest rate — significant reduction in retest rate c
Slide 14: MM Clinical Trial Program
MM Clinical Trial Program Multiple studies performed & published with Mayo Clinic to TeloView SMM train and validate the SMM risk prediction test for Telo Genomics' CAP/CLIA certified lab. Initial study (training) performed & published with Mayo TeloView NDMM Clinic, follow-up study in development O
Slide 15: Alzheimer's: Huge Challenge, Huge Opportunity
Alzheimer’s: Huge Challenge, Huge Opportunity • 57M people worldwide have dementia; most have Alzheimer’s. • Slowly erodes memory and thinking; 6th leading cause of death in the U.S. • No cure yet—current treatments postpone disease progression. • Cases could triple to 150M by 2050. • Early detectio
Slide 16: Business Model
Business Model Monetization Opportunities • Platform with multiple verticals that can be independently monetized. • Lead focus on MM MRD with strong clinical and commercial potential. • Licensing and partnering opportunities in oncology and beyond (e.g., prostate, breast). • Optional full commercial
Slide 17: Quarterly Milestones
Quarterly Milestones Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 Launching Multisite Report study results MRD Study Launching 2nd Our Report study results Multisite MRD Study File pre-sub Filing for FDA Licensing AI application with FDA Breakthrough Device Technology to Power MRD Cell Initiate Planning
Slide 18: Cap Table & Funding
Cap Table & Funding As of October 27, 2025 SHARES 100.4M OUTSTANDING SHARE PRICE 10/27/25 $0.055CAD OPTIONS 4.2M MARKET CAP $5.5MCAD WARRANTS 28.7M BURN RATE $150KCAD/ FULLY DILUTED MONTH SHARES 133.4M 2025 TELOGENOMICS . TSXV: TELO 18 Confidential
Slide 19: Transforming Cancer Diagnostic with AI and Liquid Biopsy
Corporate Update Transforming Cancer Diagnostic with AI and Liquid Biopsy 555 Richmond St West, Toronto, Canada Info@teloddx.com 647 477 9365 2025 TELOGENOMICS . TSXV: TELO 2024 TELOGENOMICS . TSXV:
Telo Genomics — Investor Presentation (December 2025) on 6ix